News

age-related macular degeneration
Failure of immune system linked to macular degeneration
Researchers from the Queen Mary University of London have found that age-related macular degeneration is potentially caused by the failure of at least one of five proteins to regulate the immune s...

Dr. Krawitz
Who's the Doctor Behind VisiVite Eye Vitamins?
It is an absolute privilege to help people to see, and I take what I do with responsibility, gravity and gratitude. Since 2001, I have treated VisiVite's supplements for ocular health with the same...

age-related macular degeneration
Researchers looking at HTRA1 protein as factor in AMD
A research team at the University of Utah found that low levels of a protein known as HTRA1 could be a trigger for the development of age-related macular degeneration (AMD) in specific individuals.

blurred vision
One in Five Teenagers Reports Sight Problems
August is Children's Eye Health and Safety Month. Did you know that 20% of teenage students reported difficulty seeing the blackboard?

covid news
Covid News Update: July 28, 2021
There have been several Covid news updates this week that directly impact you.

acceptance of covid-19 vaccines
Dr. Paul Krawitz's letter to the Unvaccinated
Delta is coming, then Epsilon, then Zeta. As the Covid-19 virus is allowed to replicate in the population in unvaccinated people, it will continue to mutate, and thus persist, because that’s how ma...

acceptance of covid-19 vaccines
94% of VisiVite eye vitamin customers are fully vaccinated against Covid-19
Vitamin Science, manufacturer of VisiVite Professional Supplements for Ocular Health, has announced that a very high percentage of their customers are fully vaccinated against the Covid-19 virus.

about dry eye
July is Dry Eye Awareness Month
According to the National Eye Institute, dry eye syndrome affects almost 16 million Americans.

age-related macular degeneration
New Anti-VEGF treatment has positive results in first clinical trial
EyePoint Pharmaceuticals recently announced results of the Phase 1 clinical trial of their new wet age-related macular degeneration treatment, EYP-1901.